DI
LGND icon

DAGCO Inc’s Ligand Pharmaceuticals LGND Stock Holding History

DAGCO Inc’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-84
Closed -$6K – 319
2023
Q4 		$6K Buy
+84
New +$4.96K 0.01% 221

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAGCO Inc's LGND Position: Q1 2024 in Review

DAGCO Inc sold out of Ligand Pharmaceuticals (LGND) in Q1 2024, closing a stake of 84 shares — an estimated $6K sold.

DAGCO Inc first reported a position in LGND in Q4 2023 and held it in 1 quarter. The position peaked at $6K in Q4 2023. 222 funds tracked by Wall St. Rank hold LGND as of Q1 2024.

  • DAGCO Inc reported no remaining Ligand Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • DAGCO Inc sold 84 Ligand Pharmaceuticals shares in Q1 2024, an estimated $6K.
  • DAGCO Inc first reported a position in Ligand Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • DAGCO Inc's Ligand Pharmaceuticals position peaked at $6K in Q4 2023.
  • 222 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2024.

Based on DAGCO Inc's 13F filing for Q1 2024, filed 15 May 2024.